Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY).

Cohan SL, Moses H, Calkwood J, Tornatore C, LaGanke C, Smoot KE, Meka V, Okwuokenye M, Hotermans C, Mendoza JP, Mann MK, Meltzer LA.

Mult Scler Relat Disord. 2018 May;22:27-34. doi: 10.1016/j.msard.2018.02.028. Epub 2018 Feb 26.

2.

In situ forming phase-inversion implants for sustained ocular delivery of triamcinolone acetonide.

Sheshala R, Hong GC, Yee WP, Meka VS, Thakur RRS.

Drug Deliv Transl Res. 2018 Feb 26. doi: 10.1007/s13346-018-0491-y. [Epub ahead of print]

PMID:
29484530
3.

Investigation on solution-to-gel characteristic of thermosensitive and mucoadhesive biopolymers for the development of moxifloxacin-loaded sustained release periodontal in situ gels.

Sheshala R, Quah SY, Tan GC, Meka VS, Jnanendrappa N, Sahu PS.

Drug Deliv Transl Res. 2018 Feb 1. doi: 10.1007/s13346-018-0488-6. [Epub ahead of print]

PMID:
29392681
4.

Immune response to vaccines is maintained in patients treated with dimethyl fumarate.

von Hehn C, Howard J, Liu S, Meka V, Pultz J, Mehta D, Prada C, Ray S, Edwards MR, Sheikh SI.

Neurol Neuroimmunol Neuroinflamm. 2017 Nov 15;5(1):e409. doi: 10.1212/NXI.0000000000000409. eCollection 2018 Jan.

5.

Evaluation of Potential Drug-Drug Interaction Between Delayed-Release Dimethyl Fumarate and a Commonly Used Oral Contraceptive (Norgestimate/Ethinyl Estradiol) in Healthy Women.

Zhu B, Nestorov I, Zhao G, Meka V, Leahy M, Kam J, Sheikh SI.

Clin Pharmacol Drug Dev. 2017 Nov;6(6):604-613. doi: 10.1002/cpdd.377. Epub 2017 Aug 7.

6.

A comprehensive review on polyelectrolyte complexes.

Meka VS, Sing MKG, Pichika MR, Nali SR, Kolapalli VRM, Kesharwani P.

Drug Discov Today. 2017 Nov;22(11):1697-1706. doi: 10.1016/j.drudis.2017.06.008. Epub 2017 Jul 3. Review.

PMID:
28683256
7.

Lipid based nanocarriers system for topical delivery of photosensitizers.

Md S, Haque S, Madheswaran T, Zeeshan F, Meka VS, Radhakrishnan AK, Kesharwani P.

Drug Discov Today. 2017 Aug;22(8):1274-1283. doi: 10.1016/j.drudis.2017.04.010. Epub 2017 Apr 27. Review.

PMID:
28456749
8.

Application of diverse natural polymers in the design of oral gels for the treatment of periodontal diseases.

Ganguly A, Ian CK, Sheshala R, Sahu PS, Al-Waeli H, Meka VS.

J Mater Sci Mater Med. 2017 Mar;28(3):39. doi: 10.1007/s10856-017-5852-4. Epub 2017 Jan 31.

PMID:
28144851
9.

Recent Advances in Non-Invasive Delivery of Macromolecules using Nanoparticulate Carriers System.

Shadab M, Haque S, Sheshala R, Meng LW, Meka VS, Ali J.

Curr Pharm Des. 2017;23(3):440-453. doi: 10.2174/1381612822666161026163201. Review.

PMID:
27784250
10.
11.

Production, Characterization and Evaluation of Kaempferol Nanosuspension for Improving Oral Bioavailability.

Qian YS, Ramamurthy S, Candasamy M, Shadab M, Kumar RH, Meka VS.

Curr Pharm Biotechnol. 2016;17(6):549-55.

PMID:
26813303
12.

Formulation of Gastric Floating System Using Bio-Sourced Terminalia Catappa Gum and in vivo Evaluation.

Meka VS, Murthy Kolapalli VR.

Curr Drug Deliv. 2016;13(6):971-81.

PMID:
26452534
13.

Opportunities for Nano-Formulations in Type 2 Diabetes Mellitus Treatments.

Jeevanandam J, Danquah MK, Debnath S, Meka VS, Chan YS.

Curr Pharm Biotechnol. 2015;16(10):853-70. Review.

PMID:
26212563
14.
15.

Preparation and in vitro characterization of a non-effervescent floating drug delivery system for poorly soluble drug, glipizide.

Meka VS, Pillai S, Dharmalingham SR, Sheshala R, Gorajana A.

Acta Pol Pharm. 2015 Jan-Feb;72(1):193-204.

16.

A comparison of mckenzie therapy with electrophysical agents for the treatment of work related low back pain: A randomized controlled trial.

Murtezani A, Govori V, Meka VS, Ibraimi Z, Rrecaj S, Gashi S.

J Back Musculoskelet Rehabil. 2015;28(2):247-53. doi: 10.3233/BMR-140511.

PMID:
25159291
17.

The effect of land versus aquatic exercise program on bone mineral density and physical function in postmenopausal women with osteoporosis: a randomized controlled trial.

Murtezani A, Nevzati A, Ibraimi Z, Sllamniku S, Meka VS, Abazi N.

Ortop Traumatol Rehabil. 2014 May-Jun;16(3):319-25. doi: 10.5604/15093492.1112533.

PMID:
25058107
18.

Design and evaluation of a gastroretentive drug delivery system for metformin HCl using synthetic and semi-synthetic polymers.

Meka VS, Gorajana A, Dharmanlingam SR, Kolapalli VR.

Invest Clin. 2013 Dec;54(4):347-59.

PMID:
24502177
19.
20.

Thermal sintering: a novel technique in the design of gastroretentive floating tablets of propranolol HCl and its evaluation.

Meka VS, Songa AS, Nali SR, Battu JR, Kukati L, Kolapalli VR.

Invest Clin. 2012 Sep;53(3):223-36.

PMID:
23248967
21.

Characterization and in vitro drug release studies of a natural polysaccharide Terminalia catappa gum (Badam gum).

Meka VS, Nali SR, Songa AS, Kolapalli VR.

AAPS PharmSciTech. 2012 Dec;13(4):1451-64. doi: 10.1208/s12249-012-9873-5. Epub 2012 Oct 23.

22.

Design and in vitro evaluation of effervescent gastric floating drug delivery systems of propanolol HCl.

Meka VS, Songa AS, Nali SR, Battu JR, Kolapalli VR.

Invest Clin. 2012 Mar;53(1):60-70.

PMID:
22524109
23.

An in vitro and in vivo investigation into the suitability of compression coated tablets of indomethacin for the treatment of rheumatoid arthritis which follow circadian rhythms.

Songa AS, Meka VS, Nali SR, Kolapalli VR.

Drug Dev Ind Pharm. 2013 Mar;39(3):447-56. doi: 10.3109/03639045.2012.662509. Epub 2012 Mar 2.

PMID:
22380574
24.

Low back pain predict sickness absence among power plant workers.

Murtezani A, Hundozi H, Orovcanec N, Berisha M, Meka V.

Indian J Occup Environ Med. 2010 Aug;14(2):49-53. doi: 10.4103/0019-5278.72241.

25.

Prototype of a breath-based analysis system for medication compliance monitoring.

Meka VV, Lutz BJ, Melker RJ, Euliano NR.

J Breath Res. 2007 Dec;1(2):026006. doi: 10.1088/1752-7155/1/2/026006. Epub 2007 Dec 6.

PMID:
21383440
26.

Clinical isolates of Staphylococcus aureus from 1987 and 1989 demonstrating heterogeneous resistance to vancomycin and teicoplanin.

Rybak MJ, Cha R, Cheung CM, Meka VG, Kaatz GW.

Diagn Microbiol Infect Dis. 2005 Feb;51(2):119-25.

PMID:
15698717
27.

Antimicrobial resistance to linezolid.

Meka VG, Gold HS.

Clin Infect Dis. 2004 Oct 1;39(7):1010-5. Epub 2004 Sep 10. Review.

PMID:
15472854
28.

Reversion to susceptibility in a linezolid-resistant clinical isolate of Staphylococcus aureus.

Meka VG, Gold HS, Cooke A, Venkataraman L, Eliopoulos GM, Moellering RC Jr, Jenkins SG.

J Antimicrob Chemother. 2004 Oct;54(4):818-20. Epub 2004 Sep 3.

PMID:
15347637
29.

Persistent bacteremia due to methicillin-resistant Staphylococcus aureus infection is associated with agr dysfunction and low-level in vitro resistance to thrombin-induced platelet microbicidal protein.

Fowler VG Jr, Sakoulas G, McIntyre LM, Meka VG, Arbeit RD, Cabell CH, Stryjewski ME, Eliopoulos GM, Reller LB, Corey GR, Jones T, Lucindo N, Yeaman MR, Bayer AS.

J Infect Dis. 2004 Sep 15;190(6):1140-9. Epub 2004 Aug 12.

PMID:
15319865
30.

Linezolid resistance in sequential Staphylococcus aureus isolates associated with a T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA.

Meka VG, Pillai SK, Sakoulas G, Wennersten C, Venkataraman L, DeGirolami PC, Eliopoulos GM, Moellering RC Jr, Gold HS.

J Infect Dis. 2004 Jul 15;190(2):311-7. Epub 2004 Jun 9.

PMID:
15216466
31.

Bellows-less lung system for the human patient simulator.

Meka VV, van Oostrom JH.

Med Biol Eng Comput. 2004 May;42(3):413-8.

PMID:
15191088
32.

Endocarditis caused by Staphylococcus aureus with reduced susceptibility to vancomycin.

Woods CW, Cheng AC, Fowler VG Jr, Moorefield M, Frederick J, Sakoulas G, Meka VG, Tenover FC, Zwadyk P, Wilson KH.

Clin Infect Dis. 2004 Apr 15;38(8):1188-91. Epub 2004 Apr 5.

PMID:
15095227

Supplemental Content

Support Center